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ABSTRACT
Background. Glomerulonephritis associated with anti-
neutrophil cytoplasmic antibodies (ANCA) is associated with
increased mortality and a high risk of end-stage renal disease
(ESRD). Here, we investigated whether the prognosis has
improved over the last 25 years.
Methods. Patients were identiﬁed in the Norwegian Kidney
Biopsy Registry. We included all patients with pauci-immune
crescentic glomerulonephritis and a positive ANCA test from
1988 to 2012. Deaths and ESRD in the cohort were identiﬁed
through record linkage with the Norwegian Population Regis-
try (deaths) and the Norwegian Renal Registry (ESRD). Out-
comes of patients diagnosed in 1988–2002 were compared
with outcomes of patients diagnosed in 2003–12.
Results. A cohort of 455 patients with ANCA-associated
glomerulonephritis was identiﬁed. The mean follow-up was
6.0 years (range, 0.0–23.4). During the study period, 165
(36%) patients died and 124 (27%) progressed to ESRD. Com-
pared with patients diagnosed in 1988–2002, those diagnosed
in 2003–12 had higher mean initial estimated glomerular ﬁl-
tration rates (37 versus 27 mL/min/1.73 m2) and lower risk of
ESRD (1-year risk: 13 versus 19%; 10-year risk: 26 versus
37%). The composite endpoint, ESRD or death within 0–1
year after diagnosis, was reduced from 34 to 25%. In patients
over 60 years old, 1-year mortality fell from 33 to 20%.
Conclusions. In Norwegian patients with ANCA-associated
glomerulonephritis, prognosis was signiﬁcantly better in
2003–12 compared with 1988–2002. This improvement was
probably partly due to a shorter diagnostic delay, and better
therapeutic management in older patients.
Keywords: ANCA-associated glomerulonephritis, diagnostic
delay, end-stage renal disease, mortality, prognosis
INTRODUCTION
Anti-neutrophil cytoplasmic antibody (ANCA)-associated glom-
erulonephritis (AAGN) is the most frequent form of the rapidly
progressive glomerulonephritis syndrome. AAGN is an import-
ant cause of end-stage renal disease (ESRD) [1, 2]. Prior to the
introduction of modern therapy, the prognosis of AAGN was
very poor, and most patients died within 1–2 years after disease
onset [3]. Cyclophosphamide (CYC) combined with corticoster-
oids (CS) was introduced as a treatment for AAGN more than
4 decades ago. This advent signiﬁcantly improved prognosis,
but morbidity and mortality remained high for several reasons
[4–9]. First, treatment was often initiated after severe irreversible
organ damage had occurred. Second, some patients had CYC-
intolerance or resistance and, until recently, there were no effective© The Author 2015. Published by Oxford University Press on behalf of ERA-
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alternative drugs for treatment. Third, both CYC and CS are as-
sociated with severe toxicity, which can be fatal. Fourth, AAGN
often recurred after long periods of remission and, unless recur-
rent episodes were treated promptly, they could cause severe
organ dysfunction, including ESRD [10–12]. Currently, rituxi-
mab has been proven as effective, but not superior, to CYC for
inducing remission in patients with ANCA-associated vasculitis
[13–15]. However, in Norway, CYC remains the ﬁrst-line treat-
ment for inducing remission in most patients with AAGN.
Despite the lack of new, safe pharmacological substances
that are more effective than CYC, a number of measures have
been taken that could improve the prognosis of patients with
AAGN. The diagnostic delay has probably been reduced by an
increased clinical awareness about AAGN and the availability
of an ANCA analysis that provides an answer within 1–2 days.
The more recent introduction of rituximab has increased the
therapeutic possibilities, particularly for patients with AAGN
that are resistant or intolerant to CYC treatment. Also, opti-
mization of CYC usage in maintenance treatments for AAGN
may have reduced treatment-related morbidity and mortality.
For example, CYC usage may be optimized by reducing doses
for older patients and patients with advanced renal failure; by
transitioning patients from oral to intravenous CYC; and by
substituting CYC with other, presumably safer agents, like
azathioprine (AZA) after achieved remission. Finally, the diag-
nostic delay, and thus, the risk of ESRD may have been
reduced by the increased awareness that life-long surveillance
is necessary to detect recurrence in patients with AAGN [16–19].
A few recent reports have shown an improved prognosis in
patients with ANCA-associated vasculitis over time, but speciﬁc
data are limited for patients with biopsy-proven AAGN [20–22].
In Norway, since 1988, all patients with kidney biopsies that
showed AAGN have been registered in the Norwegian Kidney
Biopsy Registry (NKBR). Here, we studied the prognosis in pa-
tients with AAGN and compared outcomes between patients di-
agnosed in 1988–2002 versus those diagnosed in 2003–12. We
hypothesized that Norwegian patients with AAGN have experi-
enced improved survival and reduced risk of ESRD over time.
MATERIALS AND METHODS
This study was approved by the Regional Committees for
Medical and Health Research Ethics (REC south-east).
Registries used in the study
The NKBR was established in 1988. Clinical and histo-
pathological data from patients that underwent a diagnostic
kidney biopsy in Norway (current population, 5 million) were
registered starting in 1988, and the completeness of registra-
tion was estimated to be ∼90%.
The Norwegian Renal Registry is located at Oslo University
Hospital, Rikshospitalet, Norway. Starting in 1980, all patients
that started maintenance dialysis or received a kidney trans-
plant were registered in the Norwegian Renal Registry. The tax
ofﬁce currently administers the Norwegian Population Regis-
try, and all deaths are registered on a weekly basis. Information
regarding the causes of death is recorded on the compulsory
Norwegian death certiﬁcate, and this information is registered
in the Cause of Death Registry, administered by Statistics
Norway. The unique, 11-digit, Norwegian social security number
made linking the different registries simple and reliable.
Identiﬁcation of the study population
All patients were included when they had a ﬁrst time
kidney biopsy that showed a crescentic pauci-immune pattern
and a documented positive ANCA test.
Observation period, identiﬁcation and deﬁnition
of study endpoints
The total follow-up (TFU) period of this study started on
the date of the diagnostic kidney biopsy and ended on the date
of death or on 31 December 2012. The observation period was
further stratiﬁed into short (SFU = 0–1 years) and long
(LFU > 1 years) follow-up periods. In the TFU period, the
primary endpoints were progression to ESRD [commence-
ment of chronic renal replacement therapy (RRT)] and stan-
dardized mortality ratio (SMR). In the SFU period, the study
endpoints were all-cause deaths, SMR and ESRD. In the LFU
period, the primary endpoints were SMR and ESRD. ESRD
and deaths in the cohort were identiﬁed by linking the records
of the study cohort to the Norwegian Renal Registry (ESRD)
and the Norwegian Population Registry (deaths). Causes of
death were identiﬁed by linking the study cohort to the
Norwegian Cause of Death Registry; all deaths were categor-
ized by cause, which included active vasculitis, infection,
cardiovascular disease, malignancies and other causes.
Identiﬁcation and deﬁnition of predicting factors
in the study
Predicting factors were identiﬁed in the NKBR, and com-
parison groups were deﬁned as follows:
(i) Early versus late study cohorts: patients with diagnostic
biopsies performed before 31 December 2002 (early)
were compared with those with biopsies performed
after 31 December 2002 (late).
(ii) Age groups at time of biopsy: patients were compared in
age groups of <60 years; 60–74.9 years and ≥75 years.
(iii) Renal function groups: pre-biopsy serum creatinine
levels were converted to the estimated glomerular ﬁl-
tration rate (eGFR; modiﬁed modiﬁcation of diet in
renal disease formula, Caucasians). Patients with mean
eGFR ≥15 were compared with patients with eGFR
<15 mL/min/1.73 m2.
(iv) ANCA speciﬁcity groups: patients with cytoplasmic
(C)-ANCA (immunoﬂuorescence, IF) or anti-protein-
ase 3 (PR3) (enzyme-linked immunosorbent assay,
ELISA) were compared with those with perinuclear (P)-
ANCA (IF) or anti-myeloperoxidase (MPO) (ELISA).
(v) Proteinuria groups: groups comprised patients with
proteinuria ≥3 and those with <3 g/24 h.
(vi) Blood pressure: groups comprised patients with blood
pressures ≥ or <140/90 mmHg.
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(vii) Serum albumin: groups comprised patients with serum
albumin ≥ or <30 g/L.
Mortality analyses
We compared the mortality rate of patients with AAGN to
that of the general population by calculating SMR. The SMR
was deﬁned as the ratio between the observed and expected
number of deaths in the cohort. The expected number of
deaths was calculated based on mortality data for the Norwe-
gian population, stratiﬁed by age (20–24, 25–29 years, and so
forth), time-period (1990–94, 1995–99 and so forth) and
gender (Statistics Norway). Each participant had an expected
risk of death that varied depending on age, gender, time-
period and duration of follow-up. Thus, the expected number
of deaths in the study cohort was the sum of all of these risks.
A Poisson distribution for death incidence in the general
population was assumed in calculating the 95% conﬁdence
interval (95% CI).
First, SMR was calculated for the TFU, SFU and LFU
periods. Second, the LFU was stratiﬁed into not-RRT and
RRT periods, and the SMR was calculated separately for these
periods. Finally, the above calculations were repeated after the
TFU was stratiﬁed into early (1988–2002) and late (2003–12)
study cohorts.
Availability of ANCA test and treatment protocols
for 1988–2012
A questionnaire was sent to hospitals that treated patients
with AAGN to determine the availability and response time of
the ANCA test. The questionnaire also asked whether the insti-
tution practiced substitution of CYC with AZA in maintenance
treatments for AAGN, and when they started this practice.
Statistical methods
Continuous variables are expressed as the mean ± SD and
categorical variables are expressed as the number (%). The
χ2-test was used to compare categorical variables, and the
independent sample t-test was used to compare continuous
variables. A P-value ≤0.05 was considered signiﬁcant. Kaplan–
Meier statistics were used to compare risks of ESRD and death.
The log-rank test was used to test statistical signiﬁcance. Cox
regression statistics were used to analyse unadjusted and ad-
justed hazard ratios (HRs) for ESRD and/or death. Two ad-
justed HRs were calculated: the ﬁrst was adjusted for age,
gender and ANCA speciﬁcity; the second was adjusted for the
same factors plus the eGFR.
RESULTS
A cohort of 455 patients with AAGN was identiﬁed. The TFU
duration was 2720 patient-years, with a mean follow-up of 6.0
years (range, 0.0–23.4). The mean age was 59.6 years (SD 17),
and 55% of patients were males. Number of patients with pro-
teinuria ≥3 g/24 h was 94 (21%) and with hypertension 262
(58%). Other baseline characteristics are shown in Table 1. The
outcomes of patients in the total study cohort are shown in
Figure 1A. During the TFU period, 124/455 (27%) patients pro-
gressed to ESRD, and of those, 55/124 (44%) later died. Among
the patients who did not progress to ESRD, 110/331 (33%)
died. Thus, during the TFU, 165/455 (36%) deaths occurred.
The cumulative risk of ESRD was 16% at 1 year, 25% at 5 years,
32% at 10 years and 42% at 15 years after the AAGN diagnosis.
In the SFU period (<1 years after diagnosis), 69/455 patients
(15%) progressed to ESRD, and 75/455 (16%) patients died
(Figure 1B). Thirteen patients (3%) died after commencement
of RRT. Thus, at the end of the SFU period, 324/455 (71%)
patients without ESRD were alive, and 56/455 (12%) patients
were alive, but were RRT-dependent.
At start of the LFU period (>1 year), 324 patients were alive
without RRT (Figure 1C). Progression to ESRD occurred in
55/324 (17%) patients. The cumulative risk of ESRD was 13%
at 5 years, 22% at 10 years and 37% at 15 years. During the
LFU period, 90 patients died; of these, 48 patients had not pro-
gressed to ESRD, and 42 patients were established in RRT
before death. At the end of the LFU period, 221 patients were
alive without ESRD and 69 patients were alive with RRT.
Among the 165 deaths during the TFU, the causes of death
were active vasculitis (n = 31; 19%), infection (n = 43; 26%),
cardiovascular disease (n = 58; 35%), malignancies (n = 15;
9%) and other causes (n = 18; 11%). The causes of death in the
different observation periods and in patients with or without
RRT are shown in Figure 1A–C.
In the TFU period, the SMR was 2.8 (95% CI: 2.4–3.3). In
the SFU period, the SMR was 10.8 (95% CI: 8.6–13.5), and in
the LFU period it was 1.7 (95% CI: 1.4–2.1). In the not-RRT
part of the LFU period, the SMR was 1.1 (95% CI: 0.8–1.5),
and in the RRT part, the SMR was 4.3 (95% CI: 3.2–5.8).
Risk factors for ESRD in the TFU period
Several signiﬁcant, independent risk factors for ESRD were
identiﬁed for the TFU period (Table 2), including an initial
Table 1. Baseline characteristics of patients diagnosed with AAGN in the
early (1988–2002) and late (2002–12) study periods
All
(n = 455)
1988–2002
(n = 218)
2003–12
(n = 237)
P-
value
Mean age, years (SD) 59.6 (17) 57.6 (19) 61.5 (18) 0.02
Age ≥75 years 94 (21) 31 (14) 63 (27) 0.001
Male gender 248 (55) 137 (63) 111 (47) <0.001
C-ANCA 258 (57) 142 (65) 116 (49) <0.001
P-ANCA 197 (43) 76 (35) 121 (51) <0.001
Mean eGFR, mL/
min/1.73 m2 (SD)
32 (29) 27 (26) 37 (31) <0.001
eGFR <15 mL/min/
1.73 m2
153 (34) 95 (44) 58 (25) <0.001
S-albumin, g/L (SD) 31 (7) 31 (6) 32 (7) 0.03
Proteinuria, g/24 h
(SD)
1.8 (1.9) 2.1 (2.2) 1.6 (1.5) 0.01
Systolic BP, mmHg
(SD)
143 (22) 144 (21) 142 (22) 0.33
Diastolic BP, mmHg
(SD)
81 (11) 82 (11) 80 (12) 0.05
ANCA, anti-neutrophil cytoplasmic antibodies; C-ANCA, cytoplasmic/proteinase3
ANCA; P-ANCA, perinuclear/myeloperoxidase ANCA; eGFR, estimated glomerular
ﬁltration rate; S-albumin, serum albumin; BP, blood pressure.
Values represent the number (%), unless otherwise indicated.
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eGFR <15 mL/min/1.73 m2 (adjusted HR = 5.1), male gender
(adjusted HR = 2.1), P/MPO-ANCA (adjusted HR = 1.8) and
age bracket 60–74.9 years (adjusted HR = 0.7). Furthermore,
other risk factors for ESRD identiﬁed for the TFU period were
proteinuria ≥3.0 g/24 h (adjusted HR = 1.7, 95% CI: 1.1–2.4,
P = 0.001) and blood pressure ≥140/90 mmHg (adjusted
HR = 1.9, 95% CI: 1.2–2.9, P = 0.003), but not serum albumin
<30 g/L (adjusted HR = 0.9, 95% CI: 0.6–1.3, P = 0.54).
Risk factors for death in the SFU period
Also shown in Table 2, several signiﬁcant, independent risk
factors for 1-year mortality were identiﬁed for the SFU period.
These included an initial eGFR <15 mL/min/1.73 m2 (adjusted
HR = 2.2), age bracket of 60–74.9 years (adjusted HR = 4.0)
and age ≥75 years (adjusted HR = 8.4). Moreover, an increased
1-year mortality rate was signiﬁcantly associated with serum
albumin <30 g/L (adjusted HR, 95% CI: 1.1.1–3.1, P = 0.01).
Proteinuria ≥3.0 g/24 h and blood pressure ≥140/90 mmHg
were not signiﬁcantly associated with increased 1-year mortality.
Comparison of early (1988–2002) and late (2003–12)
study cohorts
Compared with the early study cohort, the late study cohort
had signiﬁcantly higher initial renal function, measured as the
mean eGFR (37 versus 27 mL/min/1.73 m2), and signiﬁcantly
fewer patients with eGFRs <15 mL/min/1.73 m2 (25 versus 45%)
(Table 3). As shown in Table 1, there were some important differ-
ences in the baseline characteristics of these cohorts. The late
study cohort had a higher mean age (62 versus 58 years), a larger
fraction of patients ≥75 years (27 versus 14%), a larger fraction of
female patients (53 versus 37%) and a higher frequency of type
P/MPO-ANCA (51 versus 35%) than the early study cohort.
In comparing the two cohorts, we found that, over time,
the 1-year cumulative risk of ESRD decreased from 19 to 13%,
F IGURE 1 : Flow chart shows the outcomes of 455 patients with AAGN in the study cohort. (A) All patients in the TFU period. (B) Patients
included in the short follow-up period. (C) Patients included in the long follow-up period. AAGN, anti-neutrophil cytoplasmic antibody-
associated glomerulonephritis; ESRD, end-stage renal disease.
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and the 10-year risk decreased from 37 to 26% (Figure 2). In the
Cox regression model, the risk of ESRD changed with different
adjustments. For the early study period, the HR adjusted for
age, gender and ANCA was 1.6. However, after adding an ad-
justment for the initial eGFR, the HR decreased to 1.2, and the
difference between cohorts was not signiﬁcant (Table 4).
In comparing the two cohorts, we found that the 1-year
mortality rate decreased over time from 18 to 15% and it
decreased from 33 to 20% in those ≥60 years old (Figure 3).
In multivariate analyses, the unadjusted HR for 1-year mortal-
ity (1.3) was not signiﬁcantly different in the early compared
with the late study period (Table 4). When this was adjusted
for age, gender and ANCA (HR = 1.9), it was signiﬁcantly
higher than that of the late study period. Then, when it was
adjusted also for the initial eGFR (HR = 1.6), it was only bor-
derline signiﬁcant compared with the late study period. In a
sub-group analysis of patients ≥60 years old, the HR for 1-year
mortality was 2.4 after adjusting for age, gender and ANCA,
and 2.0 after also adjusting for the initial eGFR (Table 4).
In comparing the early and late study groups, we found that,
over time, the risk of the composite endpoint of ESRD or death
<1 year after the AAGN diagnosis (Figure 4) was reduced from
34 to 25% (all patients), from 21 to 13% (patients aged <60
years), from 38 to 25% (patients aged 60–74.9 years) and from
65 to 38% (patients aged ≥75 years). In the Cox regression ana-
lysis, the HR for ESRD or death <1 year after diagnosis was 1.8
after adjusting for age, gender and ANCA, but it decreased to
1.3 (not signiﬁcantly different from the late study group) after
also adjusting for the initial eGFR (Table 4).
During the SFU period, the difference in SMR between study
groups was only borderline signiﬁcant. The SMR was 14.8
(10.9–20.2) in the early cohort and 8.1 (5.8–11.3) in the late
cohort. Otherwise, we found no signiﬁcant differences in SMR
between the early and late study cohorts (data not shown).
Availability of ANCA test and treatment protocols
in 1988–2012
Most hospitals that treated patients with AAGN responded
to our questionnaire. All reported good availability of the
ANCA analysis, and the response time was one to two
working days at most. Historically, all hospitals used CYC to
treat AAGN, but in the last few years, some have used rituxi-
mab for induction and maintenance treatments. All respon-
dents also practiced the substitution of CYC with AZA for
maintenance treatments; this change in practice was intro-
duced between 2003 and 2008 in most hospitals.
Table 2. Multiple Cox regression analyses for ESRD and 1-year mortality in patients with AAGN
Factor N Events Unadjusted HR Adjusted HRa Adjusted HRb
HR for ESRD, TFU period
eGFR ≥15 302 53 1.0 1.0
eGFR <15 153 71 4.07 (2.8–5.8), P < 0.001 5.06 (3.5–7.4), P < 0.001
Female 207 44 1.0 1.0 1.0
Male 248 80 1.58 (1.1–2.3), P = 0.015 1.79 (1.2–2.6), P = 0.003 2.09 (1.4–3.1), P < 0.001
Age <60 years 189 64 1.0 1.0 1.0
Age 60–74.9 years 172 40 0.89 (0.6–1.3), P = 0.562 0.86 (0.6–1.3), P = 0.464 0.66 (0.4–1.0), P = 0.046
Age ≥75 years 94 20 1.09 (0.7–1.8), P = 0.736 1.05 (0.6–1.8), P = 0.861 0.76 (0.5–1.3), P = 0.316
C-ANCA 258 64 1.0 1.0 1.0
P-ANCA 197 60 1.56 (1.1–2.2), P = 0.015 1.78 (1.2–2.6), P = 0.003 1.78 (1.2–2.6), P = 0.003
HR for death, short follow-up period
eGFR ≥15 302 32 1.0 1.0
eGFR <15 153 43 2.97 (1.9–4.7), P < 0.001 2.19 (1.4–3.5), P = 0.001
Female 207 32 1.0 1.0 1.0
Male 248 43 1.16 (0.7–1.8), P = 0.536 1.33 (0.8–2.3), P = 0.241 1.44 (0.9–2.3), P = 0.134
Age <60 years 189 8 1.0 1.0 1.0
Age 60–74.9 years 172 33 4.85 (2.2–10.5), P < 0.001 5.01 (2.3–10.9), P < 0.001 4.02 (1.8–8.1), P < 0.001
Age ≥75 years 94 34 10.15 (4.7–21.9), P < 0.001 10.51 (4.8–23.1), P < 0.001 8.35 (3.8–18.6), P < 0.001
C-ANCA 258 41 1.0 1.0 1.0
P-ANCA 197 34 1.10 (0.7–1.7), P = 0.678 0.85 (0.5–1.4), P = 0.506 0.90 (0.6–1.4), P = 0.657
N, number of patients; HR, hazard ratio; eGFR, estimated glomerular ﬁltration rate; ESRD, end-stage renal disease; ANCA, anti-neutrophil cytoplasmic antibodies; C-ANCA,
cytoplasmic/proteinase3 ANCA; P-ANCA, perinuclear/myeloperoxidase ANCA.
aAdjusted for age, gender and ANCA; P-values compare to the top factor in each sub-group.
bAdjusted for age, gender, ANCA, and eGFR; P-values compare to the top factor in each sub-group.
Table 3. Baseline eGFR, stratiﬁed by age and study period
Age group Mean eGFR (SD) P-value Patients with eGFR <15 (%) P-value
1988–2012 1988–2002 2003–2012 Early versus late 1988–2012 1988–2002 2003–2012 Early versus late
All 32 (29) 27 (26) 37 (31) <0.001 34% 44% 25% <0.001
<60 years 42 (34) 35 (30) 52 (37) 0.001 25% 34% 13% 0.001
60–74.9 years 27 (23) 21 (19) 32 (26) 0.002 36% 48% 25% 0.002
≥75 years 23 (22) 17 (17) 26 (24) 0.037 47% 65% 38% 0.016
eGFR, estimated glomerular ﬁltration rates; SD, standard deviation.
Early study period: 1988–2002; late study period: 2003–12.
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DISCUSSION
The main ﬁnding in this study was that the prognosis of
patients with AAGN in Norway improved signiﬁcantly from
the early (1988–2002) to late (2003–12) study periods. A similar
trend has been described in several other studies in patients
with ANCA-associated vasculitis. However, to our knowledge,
this was the ﬁrst, nationwide, unselected, population-based
cohort with AAGN conﬁrmed by kidney biopsies [10, 20–22].
A major complication of AAGN is progression to ESRD
[23, 24]. We found that this risk decreased substantially over
time; for the 1-year follow-up, it decreased from 19 to 13%,
and for the 10-year follow-up, it decreased from 37 to 26%.
F IGURE 2 : Kaplan–Meier plots show renal survival in 455 patients with AAGN stratiﬁed by early (1988–2002) and late (2003–12) study
periods. (A) All patients. (B) Patients aged <60 years. (C) Patients aged ≥60 years. AAGN, anti-neutrophil cytoplasmic antibodies associated
glomerulonephritis; ESRD, end-stage renal disease.
Table 4. Multiple Cox regression analyses compare the risk of ESRD, the 1-year mortality and the 1-year risk of ESRD or death for patients with AAGN in
1988–2002 versus 2003–12
N Events Unadjusted HR Adjusted HRa Adjusted HRb
HR ESRD 1988–2002 versus 2003–12
2003–12 237 44 1.0 1.0 1.0
1988–2002 218 80 1.54 (1.0–2.3), P = 0.029 1.57 (1.1–2.3), P = 0.026 1.15 (0.8–1.7), P = 0.515
HR 1-year mortality 1988–2002 versus 2003–12
2003–12 237 35 1.0 1.0 1.0
1988–2002 218 40 1.31 (0.8–2.1), P = 0.243 1.87 (1.2–3.0), P = 0.011 1.61 (1.0–2.6), P = 0.056
HR 1-year mortality patients age ≥60 years 1988–2002 versus 2003–12
2003–12 154 30 1.0 1.0 1.0
1988–2002 112 37 1.99 (1.2–3.2), P = 0.005 2.35 (1.4–3.9), P = 0.001 2.01 (1.2–3.4) P = 0.009
HR 1-year ESRD/death 1988–2002 versus 2003–12
2003–12 237 58 1.0 1.0 1.0
1988–2002 218 73 1.49(1.1–2.1), P = 0.02 1.80(1.3–2.6), P < 0.001 1.34(0.9–1.9), P = 0.12
N, number of patients; HR, hazard ratio; ESRD, end-stage renal disease.
aAdjusted for age, gender and ANCA; P-values are compared with the 2003–12 study group.
bAdjusted for age, gender, ANCA and eGFR; P-values are compared with the 2003–12 study group.
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This was an improvement of great clinical signiﬁcance, because
RRT is associated with reduced quality of life, increased mortal-
ity and high costs [25, 26]. The major mechanism of ESRD risk
reduction over time seemed to be a shorter diagnostic delay.
The mean eGFR at AAGN diagnosis increased signiﬁcantly
over time, from 27 to 37 mL/min/1.73 m2, and the fraction of
patients with eGFR <15 mL/min/1.73 m2 decreased from 44 to
25%. In the Cox regression model, the unadjusted HR for ESRD
in the early period (1.5) was signiﬁcantly higher than that in the
late period. Moreover, the HR was basically unchanged after
adjusting for age, gender and ANCA sub-type. However, when
we also adjusted for the initial eGFR, the HR dropped to 1.2.
We interpreted this to indicate that the improvement in eGFR
was a mechanistic factor, rather than a confounder.
A primary objective when treating patients with AAGN is
to avoid fatal disease courses. In our study cohort, the mortal-
ity rate was signiﬁcantly higher than expected for the Norwe-
gian population (SMR 2.8). However, high mortality rates
were only observed in the SFU period (SMR 10.8) and in pa-
tients dependent on RRT during the LFU period (SMR 4.3).
In patients that survived the ﬁrst year and did not develop
ESRD, the mortality rate was equivalent to that of the general
population, after adjusting for age and gender (SMR 1.1). The
increased mortality rate observed in patients dependent on
RRT was probably not speciﬁc to patients with AAGN. We
previously showed similar data for patients with IgA nephro-
pathy [27]. Nevertheless, it underscored the clinical import-
ance of avoiding progression to ESRD in patients with AAGN.
The main concern regarding survival in patients with
AAGN is the high 1-year mortality rate [10]. We did not
observe signiﬁcantly different short-term mortality rates in the
early (18%) versus late (15%) study periods. However, among
patients with AAGN aged ≥60 years, the 1-year mortality rate
was signiﬁcantly reduced from 33% (early cohort) to 20% (late
cohort). Of interest, in this age group, the unadjusted HR for
death at 0–1 year after AAGN diagnosis was 2.0 (P = 0.01), and
this HR remained unchanged after adjusting for age, gender,
ANCA type and eGFR. Thus, a shorter diagnostic delay did not
appear to be a major explanatory factor for the improvement in
short-term survival among older patients. We speculated that
the improvement in short-term survival might be due to greater
care taken in treating the older patients in the later compared
with the earlier study period. For example, they may have re-
ceived more frequent use of prophylactic measures, reduced
doses of CYC and more rigorous surveillance, particularly
during the induction phase of the treatment.
F IGURE 3 : Kaplan–Meier plots show 1-year survival in 455 patients with AAGN stratiﬁed by study period (1988–2002 versus 2003–12).
(A) All patients. (B) Patients aged <60 years. (C) Patients aged ≥60 years. AAGN, anti-neutrophil cytoplasmic antibodies associated
glomerulonephritis; ESRD, end-stage renal disease.
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The risk of the composite endpoint, ESRD or death, in the
SFU period decreased from 34% (early cohort) to 25% (late
cohort), which clearly indicated a clinically relevant improve-
ment. In death-censored analyses, a reduced mortality rate
could result in an increased risk of ESRD, because death and
ESRD frequently occur concurrently, and they may compete as
endpoints in the clinical setting of AAGN in older patients.
Theoretically, a less toxic, but also less effective, treatment
regimen could result in both decreasing the mortality rate and
increasing the risk of ESRD. However, it was reassuring that,
in our study cohort, the observed improvement in short-term
survival-rate was not linked to an increased risk of ESRD; the
1-year risk of ESRD decreased from 18% (early cohort) to 15%
(late cohort) among patients aged ≥60 years.
The prognosis of patients with AAGN was better in the
LFU than in the SFU period. The mortality risk was, except in
patients with RRT, similar to the age- and gender-adjusted
general population. The annual risk of ESRD was 2–3% per
year of follow-up. Because the death rate did not increase, we
did not investigate the composite ESRD or death endpoint in
the LFU period. In fact, the prognosis of AAGN in the LFU
period was similar to our previous ﬁnding in patients with IgA
nephropathy [27]. There were no signiﬁcant differences in
prognosis between the early as compared with late cohort in
the LFU period.
The overall prognosis in our study cohort was quite similar
to that of previous study cohorts from other countries. A sub-
stantial improvement in renal function at the time of AAGN
diagnosis was also found in a recent study from the Nether-
lands. In that study, serum creatinine fell from ∼450 µmol/L
(in 1979–2000) to 282 µmol/L (in 2001–09) [21]. Most studies
reported that the long-term risk of ESRD was 20–40%, similar
to our ﬁndings [9, 20, 28, 29]. Our ﬁnding that the 1-year
overall mortality rate was 17% was consistent with previous
reports from unselected study cohorts [21]. Finally, our SMR
of 2.8 closely resembled the 2.7 SMR found in a study on pa-
tients recruited from four clinical European Vasculitis Study
Group (EUVAS) trials [10].
This study showed that the prognosis of AAGN signiﬁcant-
ly improved from the 1988–2002 period to the 2003–12
period. However, even in the late study period, the 1-year mor-
tality rate was 15%, the 1-year risk of ESRD or death was 25%
and the 10-year cumulative risk of ESRD was 26%. Thus, there
remains room for improvement. Further reduction in diagnos-
tic delay may reduce the risk of ESRD. Optimization of treat-
ment protocols, particularly for older patients, may reduce the
short-term mortality from AAGN [28, 30]. More research is
needed to ﬁnd new solutions to these challenges.
The major strengths of this study were the large, nation-
wide, population-based, unselected nature of the study cohort
F IGURE 4 : Kaplan–Meier plots show 1-year risk of ESRD or death in 455 patients with AAGN stratiﬁed by study period (1988–2002 versus
2003–12). (A) All patients. (B) Patients aged <60 years. (C) Patients aged 60–74.9 years. (D) Patients aged ≥75 years. AAGN, anti-neutrophil
cytoplasmic antibodies associated glomerulonephritis; ESRD, end-stage renal disease.
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and the very long observation period with many clinically
important (ESRD/death), reliably identiﬁed endpoints. This
study also had some weaknesses. Because the NKBR had a
purely renal focus, we could not categorize patients according
to non-renal vasculitis activity. For example, we could not use
the Birmingham vasculitis activity score. Furthermore, the
histological data in the NKBR were, unfortunately, not sufﬁ-
ciently speciﬁc to apply the recently published histopathologic
classiﬁcation system for AAGN (focal/crescentic/mixed/sclerotic).
Furthermore, we did not have detailed data on individual
treatments; thus, we could not analyse the effects of different
treatment protocols. Another limitation was that patients with
AAGN without kidney-biopsy were not included in the study
cohort, and such patients are not registered in the NKBR.
In summary, we have demonstrated that the prognosis of
AAGN has improved signiﬁcantly from 1988–2002 to 2003–12.
Nevertheless, morbidity and mortality remain major concerns.
More research is needed to identify strategies that can reduce
diagnostic delay. Development of safer therapeutic strategies is
also needed, speciﬁcally for older patients with AAGN.
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